Evaluation and treatment results of trimodality therapy for advanced esophageal squamous cell carcinoma
- 15 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Esophagus
- Vol. 18 (2), 181-186
- https://doi.org/10.1007/s10388-020-00779-w
Abstract
Objectives The prognosis for highly advanced esophageal squamous cell carcinoma (ESCC) remains poor, and there is currently no standard treatment. The purpose of this study was to examine the benefits of trimodality therapy [chemoradiation plus surgery, (CRT + S)] by evaluating the surgical outcomes of patients with ESCC in Keiyukai Sapporo Hospital, Japan. We assessed the preoperative and postoperative adverse events, treatment effects of preoperative CRT, metastatic diagnosis of the dissected lymph nodes, and survival. Patients and methods Between 2012 and 2018, 148 patients with highly advanced ESCC who underwent preoperative CRT + S were analyzed for diagnosis and staging, preoperative complications, clinical and histopathological effects of CRT in the resected specimens, survival rates, and recurrences. Results The grade 3 and higher complications of preoperative CRT were neutropenia in 3 cases and thrombocytopenia in 1 case. Among the postoperative complications, there were 2 cases (1.4%) of direct surgical death, only tracheobronchial bleeding and liver failure. Using the 11th edition of the classification of esophageal cancer by the Japanese Esophageal Society, 60 patients (40.5%) were classified as grade 3 (negative for cancer cells, pathological complete response). However, 20 of them (33.3%) had metastatic tumor cells in the lymph nodes. The overall 5-year survival rate was 58.5%. Including references to the pathological findings and recurrence patterns, there is no effective diagnostic method for selecting the subsequent approach based on the effectiveness of CRT. Conclusion Planned surgery following CRT was the only solution for achieving better treatment results. CRT + S is a promising treatment with low direct surgical mortality.Keywords
This publication has 15 references indexed in Scilit:
- Comprehensive registry of esophageal cancer in Japan, 2012Esophagus, 2019
- Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinomaCancer Science, 2013
- Diagnostic value of 18F-FDG PET/CT for lymph node metastasis of esophageal squamous cell carcinomaSurgery Today, 2013
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerThe New England Journal of Medicine, 2012
- Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysisThe Lancet Oncology, 2011
- Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal CancerJournal of Clinical Oncology, 2007
- Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysisThe Lancet Oncology, 2007
- The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlationEuropean Radiology, 2006
- A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancerThe American Journal of Surgery, 2003